During the past decade, Vermont Lung Center conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 10 clinical trials were completed, i.e. on average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vermont Lung Center" #1 sponsor was "Vertex Pharmaceuticals Incorporated" with 6 trials, followed by "University of Vermont" with 5 trials sponsored, "United Therapeutics" with 3 trials sponsored, "FibroGen" with 2 trials sponsored and "JHSPH Center for Clinical Trials" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vermont Lung Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 5 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "American Lung Association" with 1 trials as a collaborator, "American Lung Association Asthma Clinical Research Centers" with 1 trials as a collaborator and "Baylor College of Medicine" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Vermont Lung Center" are "Asthma" (7 trials), "Cystic Fibrosis" (7 trials), "Idiopathic Pulmonary Fibrosis" (6 trials), "Pulmonary Hypertension" (3 trials) and "COPD" (2 trials). Many other conditions were trialed in "Vermont Lung Center" in a lesser frequency.

Most popular intervention types in "Vermont Lung Center" are "Drug" (23 trials), "Behavioral" (2 trials), "Device" (2 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "IVA" (5 trials), "ELX/TEZ/IVA" (2 trials), "Placebo (matched to ELX/TEZ/IVA)" (2 trials) and "Placebo (matched to IVA)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Vermont Lung Center" are 29 trials for "All" genders.

Currently, there are NaN active trials in "Vermont Lung Center". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in Vermont Lung Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Vermont Lung Center, 3 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".